News Release 

Study tests 'medically tailored' meals for patients with lung cancer to fight malnutrition

Ohio State University Comprehensive Cancer Center


IMAGE: Colleen Spees, PhD, RD, samples a meal made for patients at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.... view more 

Credit: The Ohio State University Comprehensive Cancer Center

A new clinical trial at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James) aims to reduce malnutrition among patients with lung cancer by offering nutritional counseling and medically tailored meals to at-risk patients.

The project is funded by a $2.3 million research grant from Bristol-Myers Squibb Foundation, awarded to Colleen Spees, PhD, RD, and Carolyn Presley, MD, MPH of the OSUCCC - James. The study will begin in December 2019 and open to recruitment in August 2020 at the OSUCCC -James, Tufts Medical Center, Fox Chase Cancer Center and MD Anderson Cancer Center. Dr. Spees serves as co-principal investigator (PI) of the overall study protocol with Fang Fang Zhang, MD, PhD, of the Friedman School of Nutrition Science and Policy at Tufts University. Dr. Presley serves as PI of the Ohio State University clinical trial site.

An estimated 70% of all patients with lung cancer are malnourished at some point in their treatment. Malnutrition can lead to disruptions in care that reduce overall quality of life and treatment effectiveness.

"When compared with other forms of cancer, lung cancer disproportionately affects vulnerable populations - those who are economically disadvantaged, uninsured, racial/ethnic minorities, older adults and rural residents," says Dr. Spees, who serves as an associate professor in The Ohio State University College of Medicine, School of Health and Rehabilitation Sciences. "These patients often experience a double-hit because they have limited resources, resulting in inadequate access to health care and nutritious foods. Timely, effective and tailored nutrition interventions are a critical component in countering lung cancer disparities among these vulnerable populations."

Study Design

For this randomized study, the research team will recruit up to 150 newly diagnosed patients with lung cancer across all four medical centers set to undergo systemic therapy, multi-modal therapy or post-surgery adjuvant therapy (chemotherapy alone or followed by radiation therapy). Patients in the intervention group will receive behavioral-based, remote medical nutrition therapy and home-delivered, medically tailored meals.

Although nutrition is a modifiable risk factor for lung cancer-associated morbidity and mortality, researchers note it remains one of the leading causes of failing health in this patient population.

"Our goal is to help patients achieve optimal nutritional status so they remain strong throughout the course of treatment and recovery. Providing medically tailored meals that address a patient's specific nutritional needs while undergoing treatment is emerging as a promising strategy to improve the overall health outcomes of our patients," says Dr. Presley, a medical oncologist who specializes in the treatment of lung cancer at the OSUCCC - James.


Lung cancer is the No. 1 cause of cancer-related deaths among both men and women, according to the American Cancer Society. More people die in the United States annually of lung cancer than of colon, breast and prostate cancers combined.

To learn more about lung cancer treatment or clinical trials at the OSUCCC - James, visit or call 1-800-293-5066.

About the OSUCCC - James

The OSUCCC - James strives to create a cancer-free world by integrating scientific research with excellence in education and patient-centered care, a strategy that leads to better methods of prevention, detection and treatment. Ohio State is one of only 51 National Cancer Institute (NCI)-designated Comprehensive Cancer Centers and one of only a few centers funded by the NCI to conduct both phase I and phase II clinical trials on novel anticancer drugs sponsored by the NCI. As the cancer program's 356-bed adult patient-care component, The James is one of the top cancer hospitals in the nation as ranked by U.S. News & World Report and has achieved Magnet® designation, the highest honor an organization can receive for quality patient care and professional nursing practice. At 21 floors and with more than 1.1 million square feet, The James is a transformational facility that fosters collaboration and integration of cancer research and clinical cancer care. For more information, visit

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.